BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,805,434 | -22.8% | 1,260,547 | -7.4% | 2.87% | -11.6% |
| Q2 2023 | $111,162,836 | +0.9% | 1,361,789 | -8.3% | 3.24% | +8.8% |
| Q1 2023 | $110,177,121 | -31.0% | 1,485,067 | -22.9% | 2.98% | -30.0% |
| Q4 2022 | $159,721,446 | +7.7% | 1,927,141 | +269.2% | 4.26% | +9.5% |
| Q3 2022 | $148,245,000 | -23.1% | 521,991 | -6.1% | 3.89% | -13.7% |
| Q2 2022 | $192,786,000 | -23.3% | 556,157 | -4.2% | 4.50% | +80.3% |
| Q1 2022 | $251,484,000 | -19.2% | 580,743 | -3.4% | 2.50% | -4.5% |
| Q4 2021 | $311,091,000 | -5.4% | 601,329 | -11.4% | 2.62% | +25.5% |
| Q3 2021 | $328,695,000 | -9.6% | 678,324 | -16.0% | 2.08% | +0.3% |
| Q2 2021 | $363,698,000 | +0.7% | 807,753 | -14.5% | 2.08% | +1.3% |
| Q1 2021 | $361,030,000 | +18.6% | 945,278 | -1.4% | 2.05% | +69.0% |
| Q4 2020 | $304,476,000 | +24.5% | 958,829 | -2.9% | 1.21% | +6.1% |
| Q3 2020 | $244,557,000 | -7.2% | 987,193 | -1.1% | 1.14% | -13.5% |
| Q2 2020 | $263,526,000 | +39.7% | 997,940 | +0.3% | 1.32% | +11.0% |
| Q1 2020 | $188,660,000 | -12.3% | 994,941 | +1.5% | 1.19% | +5.6% |
| Q4 2019 | $215,110,000 | +20.6% | 979,957 | +7.5% | 1.13% | +15.1% |
| Q3 2019 | $178,357,000 | -5.9% | 911,523 | +0.3% | 0.98% | -0.1% |
| Q2 2019 | $189,540,000 | +8.2% | 909,112 | +3.0% | 0.98% | +2.3% |
| Q1 2019 | $175,246,000 | +42.6% | 882,634 | +3.9% | 0.96% | +27.2% |
| Q4 2018 | $122,907,000 | -25.2% | 849,277 | +5.5% | 0.75% | -9.2% |
| Q3 2018 | $164,333,000 | +35.6% | 805,121 | -1.7% | 0.83% | +34.3% |
| Q2 2018 | $121,159,000 | -11.8% | 818,920 | -10.0% | 0.62% | -10.0% |
| Q1 2018 | $137,374,000 | +13.9% | 909,522 | -2.3% | 0.69% | +12.1% |
| Q4 2017 | $120,662,000 | +15.8% | 931,400 | +8.1% | 0.61% | +21.4% |
| Q3 2017 | $104,160,000 | +6.4% | 861,616 | +3.5% | 0.50% | +1.0% |
| Q2 2017 | $97,859,000 | -11.6% | 832,847 | -23.6% | 0.50% | -8.1% |
| Q1 2017 | $110,738,000 | +2.7% | 1,089,405 | +3.9% | 0.54% | -2.5% |
| Q4 2016 | $107,800,000 | +3.1% | 1,048,337 | +9.8% | 0.56% | +19.2% |
| Q3 2016 | $104,511,000 | -45.2% | 954,443 | -43.6% | 0.47% | -41.6% |
| Q2 2016 | $190,735,000 | +16.7% | 1,691,371 | -2.2% | 0.80% | +22.1% |
| Q1 2016 | $163,412,000 | +3.2% | 1,728,863 | -1.7% | 0.66% | +12.1% |
| Q4 2015 | $158,364,000 | -1.2% | 1,759,597 | +1.5% | 0.58% | -20.1% |
| Q3 2015 | $160,284,000 | -6.9% | 1,733,553 | -0.9% | 0.73% | +11.1% |
| Q2 2015 | $172,220,000 | -1.6% | 1,748,955 | +0.2% | 0.66% | -1.8% |
| Q1 2015 | $175,006,000 | +14.7% | 1,745,003 | +5.7% | 0.67% | +11.6% |
| Q4 2014 | $152,595,000 | – | 1,651,463 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |